What indicators need to be reviewed regularly during the use of Platinib (Pujihua)?

During the use of Pralsetinib (Pralsetinib), regular review of relevant indicators is crucial to ensure treatment safety and efficacy evaluation. First of all, routine blood examination is essential, mainly monitoring the levels of white blood cells, platelets and hemoglobin. Platinib may cause hematological toxicity, such as neutropenia or thrombocytopenia, so regular review can detect abnormalities in time and prevent the risk of infection or bleeding.

Secondly, liver function and renal function tests should also be included in the scope of regular review. The metabolism of Platinib in the body mainly depends on the liver, and some metabolites are excreted through the kidneys. By reviewing indicators such as ALT, AST, total bilirubin, creatinine, and urea nitrogen, abnormalities in liver and kidney function can be detected early, and dosage can be adjusted or medication discontinued based on the results to ensure medication safety.

In addition, electrocardiogram and cardiac function monitoring are also necessary. Some patients may experience cardiac adverse reactions such as prolonged QT interval while taking Platinib. Therefore, electrocardiogram examination before and during treatment can help to detect potential cardiac risks early, which is especially important for patients with previous heart disease.

Finally, imaging studies and tumor marker monitoring are used to assess response. Tumor size and changes in lesions can be observed through imaging methods such as CT, MRI, or PET-CT. ; At the same time, combined with the dynamic changes of tumor markers such as CEA and CA125, the patient's response to platinib treatment can be judged, helping doctors adjust treatment plans and achieve precise management.

Reference materials:https://www.drugs.com/